Analyst consensus rating
Mirum Pharmaceuticals Analyst Rating: Strong Buy
MIRM is rated Strong Buy by 14 analysts with a $138.21 target. As of 2026-08-30.
Direct answer
Mirum Pharmaceuticals's consensus rating is Strong Buy.
14 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $138.21.
Forecast evidence checked August 30, 2026.
Get free Mirum Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $97.46
- Average price target
- $138.21
- High price target
- $183.00
- Low price target
- $118.00
- Low target gap
- +21.1%
- Target upside
- +41.8%
- High target gap
- +87.8%
- Target range width
- 66.7%
- Consensus rating
- Strong Buy
- Analysts
- 14
- Evidence date
- August 30, 2026
- Valid through
- September 6, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Mirum Pharmaceuticals?
Mirum Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $138.21.
How far are Mirum Pharmaceuticals's low and high targets from the recorded price?
The low target implies +21.1%, while the high target implies +87.8%.
How many analysts are included in Mirum Pharmaceuticals's consensus?
The verified consensus includes 14 analysts.
How is Mirum Pharmaceuticals's target upside or downside calculated?
The average target of $138.21 is divided by the recorded price of $97.46, then one is subtracted to produce +41.8%. This does not guarantee a future return.
When was Mirum Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-30. The dataset is valid through 2026-09-06.